Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024
May 23 2024 - 10:00AM
Syntekabio (226330.KQ), a global artificial intelligence (AI) drug
discovery pioneer, today announced its participation at the BIO
International Convention 2024, where the company will highlight its
innovative AI-driven drug discovery technologies. The convention
will be held June 3-6, 2024, at the San Diego Convention Center,
San Diego, CA.
"BIO is the ideal platform to present our
AI-driven solutions," says Jongsun Jung, PhD, CEO at Syntekabio USA
Inc. "Our innovative and lab validated technologies help streamline
the drug discovery and development process, making it faster and
more efficient. We are excited to engage with industry leaders and
demonstrate how our solutions can help bring new therapies to
patients not only very fast but safely and effectively."
At the convention, Syntekabio will showcase
DeepMatcherTM, its versatile, disease-agnostic platform that
generates small molecule hits, leads, and drug candidates against
multiple targets. Additionally, the company will highlight its
in-silico biologics platforms, Neo-ARSTM and Ab-ARSTM, which enable
personalized or universal neoantigen cancer vaccine and novel
antibody drug prediction, respectively. These cutting-edge
solutions address complex challenges in drug discovery, equipping
researchers with powerful tools to develop novel and effective
therapeutics.
BIO International Convention
2024
June 3-6, San Diego, CA, USA – Booth 5435
Schedule a meeting through the partnering system
or visit the Syntekabio team at Booth 5435 to
learn how the company’s innovative AI-driven solutions can help
solve current pipeline challenges.
About Syntekabio
Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug
discovery company bringing together biology and AI/ML since 2009
and facilitating the discovery of first-in-class and best-in-class
compounds, rapidly. The company has its own supercomputer cloud,
along with a global contract research organization network to
complement and validate its computational results. Syntekabio
offers clients a one-stop shop, with technologies and tailored
services to rapidly generate and optimize drug candidates from
target to IND-enabling. Syntekabio’s disease-agnostic platform
generates a continual stream of hits, leads, and drug candidates
that are readily available for purchase. The company also
undertakes client-specific projects to identify highly promising
development candidates for specific targets and indications. Visit
the Syntekabio website at www.syntekabio.com or follow the company
on LinkedIn for the latest updates.
Contact
Media inquiries – US &
Europe:
MC Services AGEurope: Dr. Cora Kaiser+49 89 210
228 0US: Laurie Doyle+1 339 832 0752
syntekabio@mc-services.eu